Efficacy and tolerability of pegylated interferon-alpha-2a in chronic hepatitis B: a multicenter clinical experience

Dilip Ratnam, Anouk Tara Dev, Tin Nguyen, Vijaya Sundararajan, Hugh Harley, Wendy Cheng, Alice Lee, Feryy Rusli, Robert Chen, Sally Bell, Stephen Pianko, William Sievert

Research output: Contribution to journalArticleResearchpeer-review

Abstract

BACKGROUND AND AIM: Pegylated interferon-alpha (PEG-IFN) provides potential advantages over nucleos(t)ide analogues in the treatment of chronic hepatitis B (CHB) given its finite course, durability and lack of drug resistance. Much of the evidence is derived from controlled studies and it is unclear whether these results can be replicated in an everyday, non-controlled setting. The aim of this study was to examine the efficacy and tolerability of PEG-IFN-alpha2A in CHB patients in a clinical setting. METHODS: Chronic hepatitis B patients treated with PEG-IFN-alpha2A (180microg/week, 48 weeks) at five tertiary hospitals were retrospectively identified. Baseline demographic and clinical data, on-treatment virological and serological responses and adverse events (AE) were recorded. Treatment outcomes were defined as alanine aminotransferase (ALT) normalization, hepatitis B virus DNA 6log IU/mL, 9.5 advanced fibrosis). Six months after therapy 46 achieved normalization of ALT, 16 had viral loads <351 IU/mL and 32 achieved HBeAg seroconversion. 29 HBeAg negative patients were treated (75 male, 86 born in Asia, 48 had viral loads > 6log IU/mL, 24 advanced fibrosis). Six months post-treatment, 55 and 36 maintained a normalized ALT and HBV DNA <351 IU/mL, respectively. Optimal viral suppression was maintained in 50-75 of patients over 2 years of follow up. 6.5 of all patients discontinued therapy due to AEs. CONCLUSION: In everyday clinical practice PEG-IFN therapy in CHB is well tolerated and can achieve a similar efficacy to that seen in large controlled trials.
Original languageEnglish
Pages (from-to)1447 - 1453
Number of pages7
JournalJournal of Gastroenterology and Hepatology
Volume27
Issue number9
DOIs
Publication statusPublished - 2012

Cite this

Ratnam, Dilip ; Dev, Anouk Tara ; Nguyen, Tin ; Sundararajan, Vijaya ; Harley, Hugh ; Cheng, Wendy ; Lee, Alice ; Rusli, Feryy ; Chen, Robert ; Bell, Sally ; Pianko, Stephen ; Sievert, William. / Efficacy and tolerability of pegylated interferon-alpha-2a in chronic hepatitis B: a multicenter clinical experience. In: Journal of Gastroenterology and Hepatology. 2012 ; Vol. 27, No. 9. pp. 1447 - 1453.
@article{a8226e61c6cb4607b8e04718cd9526cc,
title = "Efficacy and tolerability of pegylated interferon-alpha-2a in chronic hepatitis B: a multicenter clinical experience",
abstract = "BACKGROUND AND AIM: Pegylated interferon-alpha (PEG-IFN) provides potential advantages over nucleos(t)ide analogues in the treatment of chronic hepatitis B (CHB) given its finite course, durability and lack of drug resistance. Much of the evidence is derived from controlled studies and it is unclear whether these results can be replicated in an everyday, non-controlled setting. The aim of this study was to examine the efficacy and tolerability of PEG-IFN-alpha2A in CHB patients in a clinical setting. METHODS: Chronic hepatitis B patients treated with PEG-IFN-alpha2A (180microg/week, 48 weeks) at five tertiary hospitals were retrospectively identified. Baseline demographic and clinical data, on-treatment virological and serological responses and adverse events (AE) were recorded. Treatment outcomes were defined as alanine aminotransferase (ALT) normalization, hepatitis B virus DNA 6log IU/mL, 9.5 advanced fibrosis). Six months after therapy 46 achieved normalization of ALT, 16 had viral loads <351 IU/mL and 32 achieved HBeAg seroconversion. 29 HBeAg negative patients were treated (75 male, 86 born in Asia, 48 had viral loads > 6log IU/mL, 24 advanced fibrosis). Six months post-treatment, 55 and 36 maintained a normalized ALT and HBV DNA <351 IU/mL, respectively. Optimal viral suppression was maintained in 50-75 of patients over 2 years of follow up. 6.5 of all patients discontinued therapy due to AEs. CONCLUSION: In everyday clinical practice PEG-IFN therapy in CHB is well tolerated and can achieve a similar efficacy to that seen in large controlled trials.",
author = "Dilip Ratnam and Dev, {Anouk Tara} and Tin Nguyen and Vijaya Sundararajan and Hugh Harley and Wendy Cheng and Alice Lee and Feryy Rusli and Robert Chen and Sally Bell and Stephen Pianko and William Sievert",
year = "2012",
doi = "10.1111/j.1440-1746.2011.07051.x",
language = "English",
volume = "27",
pages = "1447 -- 1453",
journal = "Journal of Gastroenterology and Hepatology",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "9",

}

Efficacy and tolerability of pegylated interferon-alpha-2a in chronic hepatitis B: a multicenter clinical experience. / Ratnam, Dilip; Dev, Anouk Tara; Nguyen, Tin; Sundararajan, Vijaya; Harley, Hugh; Cheng, Wendy; Lee, Alice; Rusli, Feryy; Chen, Robert; Bell, Sally; Pianko, Stephen; Sievert, William.

In: Journal of Gastroenterology and Hepatology, Vol. 27, No. 9, 2012, p. 1447 - 1453.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Efficacy and tolerability of pegylated interferon-alpha-2a in chronic hepatitis B: a multicenter clinical experience

AU - Ratnam, Dilip

AU - Dev, Anouk Tara

AU - Nguyen, Tin

AU - Sundararajan, Vijaya

AU - Harley, Hugh

AU - Cheng, Wendy

AU - Lee, Alice

AU - Rusli, Feryy

AU - Chen, Robert

AU - Bell, Sally

AU - Pianko, Stephen

AU - Sievert, William

PY - 2012

Y1 - 2012

N2 - BACKGROUND AND AIM: Pegylated interferon-alpha (PEG-IFN) provides potential advantages over nucleos(t)ide analogues in the treatment of chronic hepatitis B (CHB) given its finite course, durability and lack of drug resistance. Much of the evidence is derived from controlled studies and it is unclear whether these results can be replicated in an everyday, non-controlled setting. The aim of this study was to examine the efficacy and tolerability of PEG-IFN-alpha2A in CHB patients in a clinical setting. METHODS: Chronic hepatitis B patients treated with PEG-IFN-alpha2A (180microg/week, 48 weeks) at five tertiary hospitals were retrospectively identified. Baseline demographic and clinical data, on-treatment virological and serological responses and adverse events (AE) were recorded. Treatment outcomes were defined as alanine aminotransferase (ALT) normalization, hepatitis B virus DNA 6log IU/mL, 9.5 advanced fibrosis). Six months after therapy 46 achieved normalization of ALT, 16 had viral loads <351 IU/mL and 32 achieved HBeAg seroconversion. 29 HBeAg negative patients were treated (75 male, 86 born in Asia, 48 had viral loads > 6log IU/mL, 24 advanced fibrosis). Six months post-treatment, 55 and 36 maintained a normalized ALT and HBV DNA <351 IU/mL, respectively. Optimal viral suppression was maintained in 50-75 of patients over 2 years of follow up. 6.5 of all patients discontinued therapy due to AEs. CONCLUSION: In everyday clinical practice PEG-IFN therapy in CHB is well tolerated and can achieve a similar efficacy to that seen in large controlled trials.

AB - BACKGROUND AND AIM: Pegylated interferon-alpha (PEG-IFN) provides potential advantages over nucleos(t)ide analogues in the treatment of chronic hepatitis B (CHB) given its finite course, durability and lack of drug resistance. Much of the evidence is derived from controlled studies and it is unclear whether these results can be replicated in an everyday, non-controlled setting. The aim of this study was to examine the efficacy and tolerability of PEG-IFN-alpha2A in CHB patients in a clinical setting. METHODS: Chronic hepatitis B patients treated with PEG-IFN-alpha2A (180microg/week, 48 weeks) at five tertiary hospitals were retrospectively identified. Baseline demographic and clinical data, on-treatment virological and serological responses and adverse events (AE) were recorded. Treatment outcomes were defined as alanine aminotransferase (ALT) normalization, hepatitis B virus DNA 6log IU/mL, 9.5 advanced fibrosis). Six months after therapy 46 achieved normalization of ALT, 16 had viral loads <351 IU/mL and 32 achieved HBeAg seroconversion. 29 HBeAg negative patients were treated (75 male, 86 born in Asia, 48 had viral loads > 6log IU/mL, 24 advanced fibrosis). Six months post-treatment, 55 and 36 maintained a normalized ALT and HBV DNA <351 IU/mL, respectively. Optimal viral suppression was maintained in 50-75 of patients over 2 years of follow up. 6.5 of all patients discontinued therapy due to AEs. CONCLUSION: In everyday clinical practice PEG-IFN therapy in CHB is well tolerated and can achieve a similar efficacy to that seen in large controlled trials.

UR - http://www.ncbi.nlm.nih.gov/pubmed/22168789

U2 - 10.1111/j.1440-1746.2011.07051.x

DO - 10.1111/j.1440-1746.2011.07051.x

M3 - Article

VL - 27

SP - 1447

EP - 1453

JO - Journal of Gastroenterology and Hepatology

JF - Journal of Gastroenterology and Hepatology

SN - 0815-9319

IS - 9

ER -